3.0.0 79 2025-12-05T08:40:31Z 2025-12-05T08:40:31Z Senate S S 2023-01-25 118 https://www.congress.gov/bill/118th-congress/senate-bill/79 ssju00 Judiciary Committee Senate Standing Reported By 2023-03-01T21:12:25Z Markup By 2023-02-09T14:52:34Z Referred To 2023-01-25T20:42:22Z 118 1717 HR 2023-03-22 Referred to the House Committee on the Judiciary. Identical bill CRS 2023-03-01 Senate Placed on Senate Legislative Calendar under General Orders. Calendar No. 18. Calendars 2023-03-01 ssju00 Judiciary Committee Senate Committee on the Judiciary. Reported by Senator Durbin without amendment. Without written report. Committee 2023-03-01 Committee on the Judiciary. Reported by Senator Durbin without amendment. Without written report. Committee 14000 9 Library of Congress ssju00 Judiciary Committee 2023-02-09 ssju00 Judiciary Committee Senate Committee on the Judiciary. Ordered to be reported without amendment favorably. Committee 2023-01-25 ssju00 Judiciary Committee Senate Read twice and referred to the Committee on the Judiciary. IntroReferral 2023-01-25 Introduced in Senate IntroReferral 10000 9 Library of Congress D000563 Sen. Durbin, Richard J. [D-IL] Richard Durbin D IL J. N T000476 Sen. Tillis, Thomas [R-NC] Thomas Tillis R NC Roland 2023-01-25 True G000386 Sen. Grassley, Chuck [R-IA] Chuck Grassley R IA 2023-01-25 True C001088 Sen. Coons, Christopher A. [D-DE] Christopher Coons D DE A. 2023-01-25 True W000800 Sen. Welch, Peter [D-VT] Peter Welch D VT 2023-02-07 False F000062 Sen. Feinstein, Dianne [D-CA] Dianne Feinstein D CA 2023-02-07 False 2023-07-06T18:42:00Z https://www.cbo.gov/publication/59353 As reported by the Senate Committee on the Judiciary on March 1, 2023 Commerce Administrative remedies 2023-03-06T14:45:16Z Department of Commerce 2023-03-06T14:45:16Z Drug safety, medical device, and laboratory regulation 2023-03-06T14:45:16Z Food and Drug Administration (FDA) 2023-03-06T14:45:16Z Intellectual property 2023-03-06T14:45:16Z Intergovernmental relations 2023-03-06T14:45:16Z Commerce 2023-02-08T20:15:49Z

00 2023-01-25 Introduced in Senate 2023-03-24T13:56:45Z <p><b>Interagency Patent Coordination and Improvement Act of 2023 </b></p> <p>This bill establishes the Interagency Task Force on Patents to support coordination and communication between the U.S. Patent and Trademark Office (PTO) and the Food and Drug Administration (FDA) on activities relating to patents for human drugs and biological products. </p> <p>The task force's duties shall include sharing information about (1) the processes of each agency, including how each agency evaluates applications (e.g., patent applications at the PTO and new drug applications at the FDA); and (2) new approvals of patents, human drugs, biological products, and new technologies. The task force must also establish a process that requires (1) the PTO to request from the FDA information relating to certain patent applications to help patent examiners carry out their duties, (2) the FDA to provide such information to the PTO, and (3) the PTO to assist the FDA in its ministerial role of listing patents.</p>

25 2023-03-01 Reported to Senate 2023-04-06T14:20:43Z <p><b>Interagency Patent Coordination and Improvement Act of 2023 </b></p> <p>This bill establishes the Interagency Task Force on Patents to support coordination and communication between the U.S. Patent and Trademark Office (PTO) and the Food and Drug Administration (FDA) on activities relating to patents for human drugs and biological products. </p> <p>The task force's duties shall include sharing information about (1) the processes of each agency, including how each agency evaluates applications (e.g., patent applications at the PTO and new drug applications at the FDA); and (2) new approvals of patents, human drugs, biological products, and new technologies. The task force must also establish a process that requires (1) the PTO to request from the FDA information relating to certain patent applications to help patent examiners carry out their duties, (2) the FDA to provide such information to the PTO, and (3) the PTO to assist the FDA in its ministerial role of listing patents.</p>

Display Title 45 2024-07-24T15:23:47Z Short Title(s) as Introduced 101 2024-05-24T13:42:57Z Introduced in Senate IS Short Title(s) as Reported to Senate 103 2024-05-24T13:42:29Z S Senate Reported to Senate RS Official Title as Introduced 6 2023-02-02T02:44:02Z Introduced in Senate IS Reported to Senate 2023-03-01T05:00:00Z https://www.govinfo.gov/content/pkg/BILLS-118s79rs/xml/BILLS-118s79rs.xml Introduced in Senate 2023-01-25T05:00:00Z https://www.govinfo.gov/content/pkg/BILLS-118s79is/xml/BILLS-118s79is.xml 2023-03-01 Placed on Senate Legislative Calendar under General Orders. Calendar No. 18. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.